DAEJEON, South Korea, June 10, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it presented ...

In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into ...

Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

MADISON, Wis, & NORTH BETHESDA, Md., October 22, 2025--(BUSINESS WIRE)--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, ...

(RTTNews) - WuXi XDC, a global leading Contract Research, Development and Manufacturing Organization dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated ...

On June 10, Alteogen, a bio-platform company, announced that it had released preclinical experimental results on the subcutaneous (SC) formulation of antibody-drug conjugates (ADC) using the ...

WuXi XDC, a CRDMO, agreed to collaborate with Earendil Labs on WuXi XDC’s WuXiTecan-2 payload-linker technology platform. The partnership is aimed at accelerating the development of next-gen ADCs by ...

Antibody-drug conjugates (ADCs) are transforming oncology with their ability to deliver potent cytotoxic agents directly to tumor cells, combining the targeting precision of monoclonal antibodies with ...

The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a ...

SAN DIEGO – October 14 th, 2015 — Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it is expanding its ...